Literature DB >> 25268200

Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis.

Guillermo A Herrera1.   

Abstract

CONTEXT: Lesions associated with monoclonal light and heavy chains display a variety of glomerular, tubular interstitial, and vascular manifestations. While some of the entities are well recognized, including light and heavy chain deposition diseases, AL (light chain) and AH (heavy chain) amyloidosis, and light chain ("myeloma") cast nephropathy, other lesions centered on proximal tubules are much less accurately identified, properly diagnosed, and adequately understood in terms of pathogenesis and molecular mechanisms involved. These proximal tubule-centered lesions are typically associated with monoclonal light chains and have not been reported in patients with circulating monoclonal heavy chains.
OBJECTIVE: To determine the incidence of proximal tubulopathies in a series of patients with monoclonal light chain-related renal lesions and characterize them with an emphasis on clinical correlations and elucidation of molecular mechanisms involved in their pathogenesis.
DESIGN: A study of 5410 renal biopsies with careful evaluation of light microscopic, immunofluorescence, and electron microscopic findings was conducted to identify these monoclonal light/heavy chain-related lesions. In selected cases, ultrastructural immunolabeling was performed to better illustrate and understand molecular mechanisms involved or to resolve specific diagnostic difficulties.
RESULTS: In all, 2.5% of the biopsies were diagnosed as demonstrating renal pathology associated with monoclonal light or heavy chains. Of these, approximately 46% were classified as proximal tubule-centered lesions, also referred to as monoclonal light chain-associated proximal tubulopathies. These proximal tubulopathies were divided into 4 groups defined by characteristic immunomorphologic manifestations associated with specific clinical settings.
CONCLUSIONS: These are important lesions whose recognition in the different clinical settings is extremely important for patients' clinical management, therapeutic purposes, and prognosis. These entities have been segregated into 4 distinct variants, conceptualized morphologically and clinically. Specific mechanisms involved in their pathogenesis are proposed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25268200     DOI: 10.5858/arpa.2013-0493-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  17 in total

1.  Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.

Authors:  M Vignon; V Javaugue; M P Alexander; K El-Karoui; A Karras; D Roos-Weil; B Royer; B Asli; B Knebelmann; G Touchard; A Jaccard; B Arnulf; F Bridoux; N Leung; J P Fermand
Journal:  Leukemia       Date:  2016-07-20       Impact factor: 11.528

Review 2.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

3.  Light chain Fanconi syndrome in a patient with acute myeloid leukemia and monoclonal gammopathy of undetermined significance.

Authors:  Daniel W Ross; Rimda Wanchoo; Adriana Guigova; Cristina Ghiuzeli; Steven L Allen; Kenar D Jhaveri
Journal:  CEN Case Rep       Date:  2016-08-30

4.  Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era.

Authors:  Michael B Stokes; Anthony M Valeri; Leal Herlitz; Abdullah M Khan; David S Siegel; Glen S Markowitz; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

5.  Remission of light chain proximal tubulopathy in IgG λ-type multiple myeloma by lenalidomide and dexamethasone therapy.

Authors:  Shinya Kawamoto; Yuji Hidaka; Yu Kaneko; Hideo Misawa; Katsuhiro Nagahori; Atsunori Yoshino; Takamitsu Okamura; Shinichi Ban; Yoshihiko Ueda; Tetsuro Takeda
Journal:  CEN Case Rep       Date:  2019-02-05

Review 6.  Paraprotein-Related Kidney Disease: Kidney Injury from Paraproteins-What Determines the Site of Injury?

Authors:  Mona Doshi; Amit Lahoti; Farhad R Danesh; Vecihi Batuman; Paul W Sanders
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

7.  Impaired Lysosomal Function Underlies Monoclonal Light Chain-Associated Renal Fanconi Syndrome.

Authors:  Alessandro Luciani; Christophe Sirac; Sara Terryn; Vincent Javaugue; Jenny Ann Prange; Sébastien Bender; Amélie Bonaud; Michel Cogné; Pierre Aucouturier; Pierre Ronco; Frank Bridoux; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

Review 8.  Animal models of monoclonal immunoglobulin-related renal diseases.

Authors:  Christophe Sirac; Guillermo A Herrera; Paul W Sanders; Vecihi Batuman; Sebastien Bender; Maria V Ayala; Vincent Javaugue; Jiamin Teng; Elba A Turbat-Herrera; Michel Cogné; Guy Touchard; Nelson Leung; Frank Bridoux
Journal:  Nat Rev Nephrol       Date:  2018-02-19       Impact factor: 28.314

Review 9.  Extracellular vesicles mediate cellular interactions in renal diseases-Novel views of intercellular communications in the kidney.

Authors:  Ping L Zhang; Ming-Lin Liu
Journal:  J Cell Physiol       Date:  2021-01-11       Impact factor: 6.513

10.  Monotypic plasma cell interstitial nephritis as the only clinical manifestation in a patient with previously undiagnosed indolent multiple myeloma: A case report.

Authors:  Philippe Attias; Anissa Moktefi; Marie Matignon; Jehan Dupuis; Céline Debiais-Delpech; Philippe Grimbert; Philippe Lang; Vincent Audard
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.